Latest from Georgetown Lombardi Comprehensive Cancer Center


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.
John L. Marshall, MD, discusses the results of the CALGB 80405 trial and other ongoing efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.
Adding a formulation of the Coxsackievirus A21 (CAVATAK®) to ipilimumab (Yervoy) yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.
Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.
Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.
John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).
Publication Bottom Border
Border Publication
x